BDSX — BIODESIX INC

Nasdaq · Health Care · Health Care Providers & Services · CIK 1439725 ·
Last close
$15.06
Market Cap
$155.96M
52W High
$20.20
52W Low
$9.43
ADV30
65,657
Next earnings
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 25,555,000 21,350,000 -6,196,000 -7,793,000 94,637,000 25,572,000 85,505,000
Dec 2025 28,755,000 23,876,000 -1,966,000 -3,980,000 87,476,000 18,987,000 89,941,000
Sep 2025 21,768,000 17,662,000 -7,044,000 -8,716,000 88,722,000 16,604,000 90,444,000
Jun 2025 20,018,000 15,987,000 -9,693,000 -11,468,000 87,740,000 20,728,000 86,602,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-24,837,000
Investing CF
$-410,000
Financing CF
$33,217,000
CapEx
$-410,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.06
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-505,555,000
Inventory
Receivables
$9,500,000
ST Investments
EBIT TTM
$-23,949,000
Pretax Income TTM
$-31,957,000
Interest Exp TTM
$8,008,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$96,096,000
EBITDA
$-19,673,000
Free Cash Flow
$-13,779,875
Enterprise Value
$200,231,216
Total Cash
$25,572,000
Total Debt
$73,568,000
Shares Out
10,355,809
Trailing EPS
$-3.96
Book Value
$0.90
ROE
-316.5%
ROA
-17.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 88,499,000 -27,766,000 -35,265,000 87,476,000 89,941,000 -23,271,000
Dec 2024 71,323,000 -34,260,000 -42,931,000 97,244,000 76,368,000 -48,649,000
Dec 2023 49,087,000 -41,298,000 -52,146,000 99,096,000 94,516,000 -22,870,000
Dec 2022 38,212,000 -50,506,000 -65,447,000 92,906,000 72,300,000 -44,972,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.22

Peers — same industry

TickerNameMarket CapLastDaily %
AUNA AUNA S.A. $148.58M $4.93
ALPS Alps Group Inc $120.64M $0.73
XGN EXAGEN INC. $112.83M $4.67
LFMD LifeMD, Inc. $227.30M $4.70
YDES YD Bio Ltd $231.62M $3.27

News headlines (Yahoo Finance, 1h cache)

Are Medical Stocks Lagging Biodesix (BDSX) This Year?
2026-06-15 13:40 · Yahoo
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity
2026-06-09 11:16 · Yahoo
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
2026-06-08 12:22 · Yahoo
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
2026-05-28 13:40 · Yahoo
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
2026-05-25 13:55 · Yahoo
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions
2026-05-23 12:16 · Yahoo
Biodesix to Participate in Upcoming Investor Conferences
2026-05-21 10:00 · Yahoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
2026-05-12 13:40 · Yahoo
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
2026-05-11 13:17 · Yahoo
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
2026-05-07 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.